

SPHHP Research Activities Newsletter

University at Buffalo

March 2020

IN THE NEWS

Congratulations to the Following Awardees!



Katherine Balantekin, Clinical Assistant Professor of Exercise & Nutrition Sciences, is PI on a new award from National Institute of Diabetes and Digestive and Kidney Diseases/NIH for the project entitled, *The Intersection between Loss of Control Eating and Obesity: The Role of Restriction and Food Reinforcement*. The study will explore the relationships among loss of control eating, parental restriction, and the reinforcing value of food with respect to obesity risk.



Lucia Leone, Assistant Professor of Community Health and Health Behavior, received a Diversity Supplement from the National Cancer Institute for her R01 entitled, *Effectiveness and Implementation of a Research Tested Mobile Produce Market Designed to Improve Diet in Underserved Communities*. This administrative supplement will support a bachelor's degree graduate, Rosaura Romero, to pursue research training in health-related sciences while applying for admission to graduate school.



Jeffrey Miecznikowski, Associate Professor of Biostatistics, is Co-I on a new award from the National Institute of Dental & Craniofacial Research/NIH (PI: Abhiram Maddi, Periodontics & Endodontics) for the research project entitled, *Candida albicans glycosidases, DFG5 and DCW1, in virulence and pathogenesis*. The study will determine the functions of *DFG5* and *DCW1* in virulence and pathogenesis. Targeting *DFG5* and *DCW1* and their functions can lead to novel and efficacious antifungal drugs.



Kimberly Naus, Director of CAT Clients Services, is PI on two continuation awards from the NYS Justice Center for the Protection of People with Special Needs. The first is entitled, *Technology-Related Assistance for Individuals with Disabilities (TRAID) Program - Money Follows People*. The TRAID program helps people with disabilities access and acquire assistive technology. Consumers are able to use devices on a trial basis to determine the usefulness and need prior to purchase.

The second is entitled, *2016 TRAID MOU/ACCES- VR*. The program will continue to provide funds to the ACCESS-VR Buffalo District Office for purchasing devices for individuals transitioning from secondary to post-secondary settings, including work, certificate and training programs, and college, as well as individuals in job try-outs and internship programs.



Ekaterina Noyes, Professor of Epidemiology & Environmental Health, is PI on a new award from the Research Institute at Nationwide Children's Hospital/NIH for the project entitled, *School-Based Asthma Therapy (SBAT) to Reduce Disparities in Childhood Asthma: Dissemination and Implementation Evaluation*. The SBAT program is a medical management school-based intervention, originally designed in Rochester, NY, to enhance asthma self-management and improve adherence to preventive asthma care. The project will evaluate and develop a national dissemination strategy targeting caregivers and their children, healthcare providers, school administrators and personnel, hospitals, physician-hospital organization (PHOs), and insurers.



Jennifer Temple, Associate Professor of Exercise & Nutrition Sciences, is PI on a revision award from the National Institute of Diabetes and Digestive and Kidney Diseases/NIH for her R01 entitled, *Sensitization of the Reinforcing Value of Food as a Predictor of Weight Change in Adolescents*. The additional funds will build upon the preliminary findings by adding additional measures, extending the timeline to later adolescence and emerging adulthood, and developing and validating a novel measure of eating behavior, eating autonomy.

Inside this issue:

In the News	1-2
Grant Clinic	2-4
NIH Funding	
Limited	4-5
RFA	5-8
PAR	8
Foundations:	
AARP	8-9
Bill & Melinda Gates	9
Individual Actions of Sustainability	9



Guan Yu, Assistant Professor of Biostatistics, is Co-I on two awards. The first, a continuation award from the National Cancer Institute/NIH (PIs: Yun Wu Biomedical Engineering & Qiaoqiang Gan, Electrical Engineering), is entitled, *Exosome-Protein-microRNA-OneStop (Exo-PROS) biosensor: a new liquid biopsy for cancer screening and early detection*. Using the Exo-PROS biosensor that the PIs developed, the project seeks to optimize the biosensor to further improve its sensing performance, and then use lung cancer as the disease model to demonstrate its clinical utility in cancer screening and early detection.

The second is a new award from the National Institute of Dental & Craniofacial Research/NIH (PI: Jill Kramer, Oral Biology) for the project entitled, *Analysis of MyD88-mediated Immune Activation in Sjogrens Syndrome Pathogenesis*. The study seeks to identify the tissue-specific contributions of MyD88 and the mediated signaling networks that govern pSS disease pathogenesis. Insights gained by the study will reveal novel mechanisms that govern chronic inflammation in pSS and pathways that may be targeted therapeutically in pSS and other autoimmune diseases.



Jihnhue Yu, Associate Professor of Biostatistics, is PI on a new award from Florida International University/U.S. Department of Education for the project entitled, *Enhancing IEP Implementation of Children with ADHD Using Daily Report Cards: An Efficacy Trial*. The study will test the efficacy of using a daily report card (DRC) intervention as an enhancement to the individualized education program (IEP) for students with attention-deficit hyperactivity disorder. The DRC will provide teachers with a daily link to a child's IEP goals and objectives and a mechanism for providing feedback to the child and parent on progress.

GRANT CLINIC

Information from NIH on COVID-19

[NOT-OD-20-091](#)

Update: NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus

All grant applications submitted late for due dates between March 9, 2020, and May 1, 2020, will be accepted through May 1, 2020. This notice applies to all relevant funding opportunity announcements, including those that indicate no late applications will be accepted. Institutions need not request advance permission to submit late due to this declared emergency and a cover letter providing a justification is not required. NIH anticipates, but cannot guarantee, that all late applications submitted by that date will be reviewed in the council round to which they were submitted (e.g. August or October 2020). Applicants should assume that late applications submitted after May 1 may not be reviewed until meetings for the January 2021 council round (e.g., October-November 2020).

[NOT-OD-20-082](#)

NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus

When delays occur because the applicant or recipient organization is officially closed or unable to submit grant applications due to the effects of COVID-19, the NIH will consider accepting applications late, on a case-by-case basis, in accordance with the NIH Grants Policy Statement, [Section 2.3.9](#), under the following circumstances:

- Institutions must submit applications or reports as soon as possible after reopening or resuming operations so that grant applications can be submitted, not to exceed the number of days the institution was officially closed or unable to submit grant applications.
- Institutions must submit a cover letter with the applications with enough detail about the delay so that NIH staff can make a determination whether circumstances justify accepting the application late.
- Institutions need not request advance permission to submit late due to this declared emergency.

[NOT-OD-20-083](#)

General Frequently Asked Questions – Proposal Submission and Award Management Related to COVID-19

NIH is providing this information as a service to our applicant and recipient communities in the hopes it will address high-level questions that may arise in this regard. Please note that given the fact that COVID-19 and associated impacts continue to evolve, applicants and recipients are strongly encouraged to monitor the NIH website for updates.

[NOT-OD-20-086](#)

Flexibilities Available to Applicants and Recipients of Federal Financial Assistance Affected by COVID-19

NIH has implemented short-term administrative flexibilities to assist our applicants with managing administrative, financial management and audit requirements. The flexibilities offered include pre-award costs; extension of post-award financial and other reporting; prior approval requirement waivers; and grant expenses relating to salary, travel, conference fees; closeout; and audits. For specific information on these topics, please see the NIH notice. ence fees; closeout; and audits. For specific information on these topics, please see the NIH notice.

General NIH Notices

NOT-CA-20-033

Notice on Policy Regarding Minimum Level of Effort for NCI-Funded Awards

Effective immediately, PIs will be required to commit a minimum level of effort to be eligible for NCI funding through R01, U01, P01, and R21 grant mechanisms. Competing applications that do not meet the minimum criteria will not be considered for funding. In addition, a request to reduce the PI's level of effort in subsequent years of funding will not be approved if the proposed level of effort falls below the minimum level. Unless otherwise stated in the FOA, the minimum levels of effort in calendar months are:

R01/U01	Single PI	1.8 mths (15%)
	Multiple PI	1.2 mths (10% ea)
R21	PI	0.6 mths (5%)

Please see the NIH notice for additional information.

NOT-OD-20-075

Notice of Transition to New System for Issuing Certificates of Confidentiality (CoC) for Non-NIH Funded Research

NIH considers requests for CoC for non-NIH funded research to protect identifiable, sensitive research information from disclosure. The 21st Century Cures Act requires the DHHS to minimize burden, streamline the process, and reduce the time it takes to comply with the requirements associated with applying for a Certificate. As part of its efforts to implement these requirements, NIH has updated its CoC request process for non-NIH funded institutions through a new CoC online system. Users will no longer have access to the current CoC system as of March 13, 2020 – if you need a copy of a Certificate or associated documentation, you will need to download these files prior to March 13th. Additional information, such as new FAQs, is available at the NIH Certificates of Confidentiality website at <https://grants.nih.gov/policy/humansubjects/coc.htm>

NOT-OD-20-078

The NIH Sexual & Gender Minority Research Office Request for Nominations for 2020 SGM Research Investigator Awards Program

Two non-monetary awards of recognition will be offered to early-stage investigators who demonstrate both contemporary achievement in and a commitment to an area of SGM-related health research. A non-monetary award will be offered to one distinguished investigator, one leading the field of SGM research as distinguished by the length and magnitude of contribution. For eligibility criteria and information on the nomination process, please see the NIH notice.

Notice of Special Interest

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

NATIONAL INSTITUTE ON DRUG ABUSE

NOT-DA-20-020

Going Global: Using Gene Network Analyses to Understand the Etiology of SUD

Applications are encouraged that explore and/or test the role of gene networks in substance abuse disorders through the development, optimization, and/or implementation of multilevel computational, bioinformatics, statistical and/or analytical approaches that integrate at least two levels of data (e.g., genomic, epigenomic, chromatin, environmental, etc.). Applications should be submitted using one of the parent FOAs. For funding consideration, applicants must include 'NOT-DA-20-020' in box 4B of the SF424 form. **Application Due Dates:** Standard due dates

NOT-DA-20-005

Mechanistic Investigations of Psychosocial Factors Associated with Substance Use Disorders

This notice promotes research directed at elucidating the neurobiological mechanisms by which psychosocial factors during different windows of development shape the trajectory of substance use and substance use disorder. Please refer to the Notice for research objectives. Applicants should submit using one of the parent FOA, as well as [PAR-19-368](#). Applications should be submitted through the appropriate parent FOAs. For funding consideration, applicants must include "NOT-DA-20-005" in box 4B of the SF424 form. **Application Due Dates:** Standard dates apply; **Expiration Date:** September 8, 2023.

NOT-DA-20-006

Mentored Career Development Award in Large-Scale Clinical Study Development and Analysis

NIDA seeks applications to support mentored career development towards 1) clinical research involving design and collection of large-scale data, and/or 2) quantitative research on existing large-scale datasets such as the Adolescent Brain Cognitive Development (ABCD) and similar datasets (e.g., HCP). Applicants should submit using one of the Parent K

NIDA seeks applications to support mentored career development towards 1) clinical research involving design and collection of large-scale data, and/or 2) quantitative research on existing large-scale datasets such as the Adolescent Brain Cognitive Development (ABCD) and similar datasets (e.g., HCP). Applicants should submit using one of the Parent K FOAs. Please refer to the notice for appropriate FOAs, as well as a list of research objectives. Applications must include "NOT-DA-20-006" in box 4B of the SF424 form. **Application Due Dates:** Standard dates apply; **Expiration Date:** September 8, 2023.

[NOT-DA-20-030](#)

Human Molecular Genetics of Substance Use Disorders

This Notice encourages applications for research projects that identify, validate and/or functionally characterize loci, genetic variations and haplotypes that are associated with vulnerability to addiction and that potentially inform the likelihood of responsiveness to treatment. Data may be collected from the general population, special populations, recent admixed populations, and/or electronic medical records (EMR). Secondary data analysis of data collected from the general population, special populations, recent admixed populations, and/or animal models is also appropriate for this notice. Investigators are encouraged to include functional characterization, gene x gene interactions, gene x environment interactions, and gene x environment x development interactions. Applicants should submit using the appropriate parent R01, or [PAR-19-259](#); [PAR-19-345](#). Applications must include "NOT-DA-20-030" in box 4B of the SF424 form.

Application Due Dates: Standard dates apply; **Expiration Date:** September 8, 2023.

[NOT-DA-20-039](#)

Effects of Cannabis Use and Cannabinoids on the Developing Brain

NIDA is seeking applications to study the effects of cannabis and cannabinoid exposure on the developing brain, from pre-, peri-, and post-natal development through young adulthood in humans and using animal models. Please refer to the notice for research objectives. Applicants should submit using one of the parent FOAs. Applications must include "NOT-DA-20-039" in box 4B of the SF424 form. **Application Due Dates:** Standard dates apply; **Expiration Date:** September 8, 2023.

OTHER NIH INSTITUTES

[NOT-AG-20-017](#)

Digital Technology for Early Detection of Alzheimer's Disease and Related Dementias

The goal of this NOSI is to facilitate research on the use of digital signals and data as 'biomarkers' that may flag or signal early changes within individuals at risk of AD/ADRD before cognitive symptoms are evidenced by current cognitive assessment and/or brain imaging biomarkers. Applications should be submitted to [PAR-19-070 \(R01\)](#) or [PAR-19-071 \(R21\)](#). Applicants must include "NOT-AG-20-017" in box 4B of the SF424 form. This notice applies to due dates on or after **July 9, 2020 through November 13, 2021**.

Notices of Intent to Publish a Funding Opportunity Announcement

[NOT-OD-20-076](#)

Mid-Career Advancement Awards to Integrate Basic Behavioral, Biomedical, and/or Social Scientific Processes (K18); estimated release date Spring 2020; anticipated due date Spring 2021.

NIH FUNDING OPPORTUNITIES

LIMITED SUBMISSIONS

Prior approval from UB is required for the following funding opportunities. If you are interested in applying to any of the **limited submissions** listed below, please provide the OVPRED with notification through the [Limited Submissions Mailbox](#) at least 60 days prior to the sponsor's submission deadline before proceeding with an application. As of August 8, 2019, the Limited Submission Program is being managed by Dr. Joseph Balthasar, Executive Director of Research Initiatives, on behalf of the OVPRED. He may be contacted at jb@buffalo.edu or by phone at 645-3321 for any questions or advice about the limited submission process.

[RFA-ES-20-006 \(P30\)](#) – clinical trial optional

Environmental Health Sciences Core Centers (EHS CC)

As intellectual hubs for environmental health science research, the EHS CC is expected to be the thought leaders for the field and advance the goals of the NIEHS Strategic Plan (<http://www.niehs.nih.gov/about/strategicplan/>). The Core Centers provide critical research infrastructure, shared facilities, services and/or resources, to groups of investigators conducting environmental health sciences research. An EHS CC enables researchers to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively. The overall goal of an EHS CC is to identify and capitalize on emerging issues that advance improving the understanding of the relationships among

environmental exposures, human biology, and disease. **Only one application allowed per institute. Application Due Date:** May 18, 2020.

[RFA-AI-19-073 \(U01\)](#) – Clinical Research Center (CRC), clinical trial optional

[RFA-AI-19-074 \(UM1\)](#) – Clinical Research Network – Leadership Center (LC), clinical trial required

Childhood Asthma in Urban Settings

The CRC will conduct both network-wide and site-specific clinical studies and trials with the ultimate goal of developing effective asthma treatment or prevention approaches applicable to children residing in low-income urban settings. The LC will provide the overall scientific strategy and organizational structure to the CAUSE Clinical Research Network and will interact closely with the CRCs to support the conduct of multi-site clinical studies and trials. **Only one application allowed per institute. Application Due Date:** June 19, 2020

[PAR-20-106 \(P30\)](#) – clinical trial not allowed

Centers for AIDS Research (CFAR)

The CFAR program supports research and administrative infrastructure and translational HIV/AIDS research activities at institutions that receive significant HIV/AIDS funding from NIH Institutes or Centers. CFARs are designed to foster synergy and improve coordination of research, support emerging research opportunities, and promote efficiencies through resources shared by multiple independent laboratories. CFARs are intended to promote NIH HIV/AIDS research efforts at CFAR institution(s). **Only one application per institution is allowed. Application Due Date:** July 28, 2020

[PAR-20-107 \(P30\)](#) – clinical trial not allowed

Developmental Centers for AIDS Research (D-CFAR)

The purpose of this program is to provide core facilities, expertise, resources, and services not readily obtained through more traditional funding mechanisms. D-CFAR's provide support to investigators in the development of a competitive standard CFAR. The Centers will allow applicants to develop collaborations, experiment with Core facilities, and to build and strengthen any deficiencies that might adversely affect an application for a standard CFAR award. **Only one application per institution is allowed. Application Due Date:** July 28, 2020

[RFA-AG-21-019 \(P30\)](#) – clinical trial not allowed

Alzheimers Disease Research Centers (ADRC)

NIA-designated ADRCs serve as major sources of discovery into the nature of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators. **Only one application per institution is allowed. Application Due Date:** September 15, 2020

[RFA-AG-21-009 \(P30\)](#) – clinical trial optional

Artificial Intelligence and Technology Collaboratories for Aging Research

The AITC program will serve as a national resource to promote the development and implementation of artificial intelligence approaches and technology through demonstration projects to improve care and health outcomes for older Americans, including persons with dementia (PWD) and their caregivers. **Only one application per institution is allowed. Application Due Date:** October 1, 2020

REQUESTS FOR APPLICATIONS (RFA)

May Due Dates

[RFA-AG-21-008 \(U01\)](#) – clinical trial not allowed

National Longitudinal Study of Adolescent to Adult Health (Add Health) – Wave 6

This FOA invites applications for the next 5-year cycle of the National Longitudinal Study of Adolescent to Adult Health (Add Health) to include a sixth wave of data collection (Wave VI). Add Health is a nationally representative, longitudinal study of individuals primarily born from 1976 through 1982 who were first interviewed as adolescents in grades 7-12 (ages 12-19) in 1994-1995. Add Health respondents are now entering middle age. Please refer to the FOA for the goals for Wave 6. **Application Due Date:** May 18, 2020

July Due Dates

[RFA-AG-21-016 \(U01\)](#) – clinical trial optional

Planning Projects for Clinical Trials on Effects of Sustained Reductions in Caloric Intake and Related Dietary Practices in Younger and Older Persons

This FOA invites applications for 3-year planning projects for trials in either of two age ranges (25 to <50 or ≥50 years of age) to determine the effects of sustained (e.g. 5-year) caloric restriction (CR) and other interventions that modify the amount, timing, or composition of nutrient intake on risk factors for aging-related conditions and mechanisms that may influence health span and longevity. **Application Due Date:** July 23, 2020

September Due Dates

[RFA-MH-20-128 \(R01\)](#) – clinical trial not allowed

BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative

This FOA solicits applications to develop standards that describe experimental protocols that are being conducted as part of the BRAIN Initiative. It is expected that applications will solicit community input at all stages of the process. It is recommended that the first step of standard development will involve sharing data between different key groups in the experimental community in order to ensure that the developing standard will encompass the data collection efforts of those groups. The developed standard is expected to be broadly disseminated for use and widely available.

Application Due Date: September 3, 2020

October Due Dates

[RFA-AG-21-015 \(U19\)](#) –clinical trial not allowed

Network for Identification, Evaluation, and Tracking of Older Persons with Superior Cognitive Performance for Their Chronological Age

This FOA invites applications to establish a network to identify, evaluate, track, and conduct research across multiple sites on older adults with superior cognitive performance for their age. The activity would support aggregation of sufficient numbers of these individuals to advance the field's understanding of factors that promote sustained cognitive health and those that are not of primary importance. Uniform identification and uniform data collection will allow the study of the behavioral, neurological, health, genetic, environmental, and lifestyle profiles that lead to sustained cognitive and brain function in advanced age. **Application Due Date:** October 1, 2020

[RFA-AG-21-018 \(R24\)](#) –clinical trial not allowed

Artificial Intelligence and Technology Collaboratories for Aging Research Coordinating Center (AITCC)

The AITCC will serve as a hub for the AITC program and will facilitate and coordinate trans-AITC activities. The AITCC will work closely with the NIA Program Officer (e.g., maintain a centralized database to track and synthesize progress and outcomes of each Collaboratory) and, in coordination with all AITC sites, will be responsive to requests generated by key AITC site personnel, NIA, NIH, the scientific community, and the general public.

Application Due Date: October 1, 2020

[RFA-AG-21-011 \(R01\)](#) –clinical trial optional

Central and Peripheral Control of Balance in Older Adults

This FOA is driven by the need to address a major gap in our understanding of how aging impacts the vestibular system, which, when impaired, contributes to balance problems and an increased risk of falls in older adults. Additionally, given that balance impairment can be attributed to a number of factors (e.g. sensory, motor, cognitive, psychological, and vascular function), understanding the contribution of age-related vestibular loss, and how this interacts with these factors, is critical for informing interventions and treatments for balance problems and falls in older adults.

Application Due Date: October 2, 2020

Multiple Due Dates

[RFA-CA-20-004 \(R01\)](#); [RFA-CA-20-005 \(R21\)](#) –clinical trial optional

Research Answers to NCI's Provocative Questions

These FOAs support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute Provocative Questions Initiative. The current issuance of the PQ Initiative includes an updated set of 9 PQs. Please refer to the funding announcements for the updated list.

Application Due Dates: April 30, 2020; November 17, 2020

[RFA-CA-20-019 \(R21\)](#) –**Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research**

[RFA-CA-20-020 \(R33\)](#) –**Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research**

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analyses during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.

Application Due Dates: May 28, 2020; September 29, 2020

[RFA-CA-20-007 \(R21\)](#) –clinical trial optional

Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management

This FOA invites applications for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. **Application Due Dates:** June 9, 2020; November 18, 2020

[RFA-CA-20-008](#) –Early Stage Development (U01)

[RFA-CA-20-009](#) –Advanced Development (U24)

[RFA-CA-20-010](#) –Sustained Support (U24)

Informatics Technologies for Cancer Research and Management – clinical trial optional

The central mission of these FOAs is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

Application Due Dates: June 9, 2020; November 18, 2020

[RFA-NS-19-043 \(K99/R00\)](#) –clinical trial not allowed; [RFA-NS-19-044 \(K99/R00\)](#) –independent clinical trial required

BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The BRAIN Initiative is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space.

Application Due Dates: June 10, 2020; October 9, 2020; February 10, 2021; June 9, 2021; October 6, 2021; February 10, 2022; June 8, 2022; October 11, 2022

[RFA-CA-19-034 \(P20\)](#) –clinical trial optional

Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities

The P20 grants will support feasibility and planning activities to build comprehensive cancer health disparities research programs. All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations.

Application Due Dates: June 19, 2020, and October 18, 2020

[RFA-OD-20-008 \(K01\)](#) –clinical trial not allowed

[RFA-OD-20-011 \(K01\)](#) –clinical trial required

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research

This award provides support and protected time (2-5 years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Candidates for the K01 award must have a research or health-professional doctoral degree.

Application Due Dates: July 8, 2020, February 08, 2021, October 08, 2021, July 8, 2022

[RFA-OD-20-009 \(K99/R00\)](#) –clinical trial not allowed

[RFA-OD-20-010 \(K99/R00\)](#) –clinical trial required

Pathway to Independence Award in Tobacco Regulatory Research

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This program will provide independent research support during this transition in order to help awardees launch competitive, independent research careers.

Application Due Dates: July 8, 2020, February 08, 2021, October 08, 2021, July 8, 2022

[RFA-OD-19-028 \(R01\)](#) –clinical trial optional

Tobacco Regulatory Science

This FOA supports biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).

Application Due Dates: July 17, 2020, February 13, 2021

[RFA-DA-19-019 \(R43/R44\)](#) – clinical trial optional

[RFA-DA-19-020 \(R41/R42\)](#) –clinical trial optional

America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis

These FOAs invite applications from US small business concerns to develop technologies to provide science-and-research-based solutions to the opioid emergency.

Application Due Dates: September 8, 2020, April 9, 2021, September 8, 2021

[RFA-NS-20-008 \(R41/R42\); RFA-NS-20-010 \(R43/R44\)](#) –clinical trial required

[RFA-NS-20-009 \(R41/R42\); RFA-NS-20-011 \(R43/R44\)](#) –clinical trial not allowed

HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management

These FOAs aim to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management. They are focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective

pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.

Application Due Dates: September 9, 2020, January 6, 2021, April 6, 2021, September 8, 2021, January 6, 2022, April 6, 2022, and September 8, 2022

[RFA-HL-19-024 \(R25\)](#) –clinical trial not allowed

Short-Term Research Education Program to Increase Diversity in Health-Related Research

The over-arching goal of this program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce by providing research experiences and related opportunities that enrich the pool of individuals from nationally underrepresented groups who will be available to compete for research opportunities in the mission areas of importance to NHLBI.

Application Due Dates: September 10, 2020, February 26, 2021

[RFA-OD-19-022 \(R21\)](#) –clinical trial not allowed

Secondary Analyses of Existing Datasets of Tobacco Use and Health

This FOA supports research proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP).

Application Due Dates: July 20, 2020, March 8, 2021

[RFA-OD-19-021 \(R21\)](#) –clinical trial not allowed

Maximizing the Scientific Value of Existing Biospecimen Collections: Scientific Opportunities for Exploratory Research

This FOA invites applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

Application Due Dates: August 7, 2020, March 8, 2021

[RFA-ES-19-011 \(R21\)](#) –clinical trial not allowed

Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences

This FOA supports novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented.

Application Due Dates: Monthly due dates starting November 1, 2019; please refer to the RFA.

Program Announcements Reviewed by an Institute (PAR)

[PAR-20-136 \(U01\)](#) –clinical trial not allowed

Core Infrastructure Support for Cancer Epidemiology Cohorts

This FOA encourages applications for support of the core functions of Cancer Epidemiology Cohorts (CECs), as well as methodological research. This FOA is intended to support the maintenance of existing CECs infrastructure and resource sharing with broader scientific communities.

Application Due Dates: April 7, 2020; November 9, 2020; April 9, 2021; November 9, 2021; April 7, 2022; November 9, 2022

[PAR-20-139 \(R01\)](#) –clinical trial required

Investigator Initiated Extended Clinical Trial

This FOA invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of one of the participating ICs. Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application.

Application Due Dates: May 13, 2020; September 13, 2020; January 13, 2021; May 13, 2021; September 13, 2021; January 13, 2022; May 13, 2022; September 13, 2022; January 13, 2023

FOUNDATION FUNDING OPPORTUNITIES

AARP Foundation

Advancing Economic Opportunity Among Older Adults

[Direct Service, Evidenced Based Projects:](#) AARP Foundation seeks direct-service projects with evidence of

effectiveness that low-income older adults who participate in the proposed project experience an increase in economic opportunity (increased income or reduced expenditures). In general, Direct Service projects will receive range from \$100,000 to \$250,000 per year, for up to three years. **Application Due Date:** April 22, 2020

Education, Outreach and Field Building Projects: AARP Foundation works to end senior poverty by helping vulnerable older adults build economic opportunity and social connectedness. AARP seeks projects that advance economic opportunity among low-income older adults on a systemic level. A typical grant award range is up to \$150,000 per year, for up to two years. **Application Due Date:** April 22, 2020

Bill & Melinda Gates Foundation

The Bill & Melinda Gates Foundation is inviting grant proposals for the following [Grand Challenges and Grand Challenges Explorations](#) initiatives. **Application Due Date:** April 22, 2020


Accelerating Discovery for Non-Hormonal Contraceptives: Applications are sought to seek new approaches and concepts for the characterization of contraceptive drug targets, the identification of active contraceptive compounds, and the development of novel and impactful research tools with the potential to revolutionize the field of contraceptive R&D.

Improving Access to and Use of Safe and Appropriate Cesarean Section: Projects should challenges related to cesarean section: increasing access to cesarean section where it is currently inadequate, increasing quality and safety of cesarean section to reduce iatrogenic harm to both mothers and newborns, and reducing rates of non-medically indicated cesarean section.

Innovations in Materials Science for a Transformative Menstrual Health and Hygiene Product: Grand Challenges Explorations seeks transformative and innovative ideas to support the design and development of a new menstrual health and hygiene product that meets key criteria of being responsive to user needs, focusing on discreetness, affordability, and sustainability.

Innovations for Improving the Impact of Health Campaigns: Grand Challenges Explorations seeks innovative solutions that accelerate the improvement of coverage, reach, efficiency, and effectiveness of campaign-based delivery of health.

Individual Actions for Sustainability



Plant a tree

A single tree will absorb one ton of carbon dioxide over its lifetime.



HELP STOP GLOBAL WARMING

PLANT A TREE

